Revised Alexza Deal Suggests Updated Strategy For Symphony Capital

With the dissolution of Symphony Allegro and the return of the joint venture's three clinical programs to Alexza, Symphony Capital should have its exit from the $50 million investment it made in the biotech and its Staccato aerosol inhalation technology in 2006

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet